MX2012004890A - Metodos para tratar o prevenir eritema agudo. - Google Patents

Metodos para tratar o prevenir eritema agudo.

Info

Publication number
MX2012004890A
MX2012004890A MX2012004890A MX2012004890A MX2012004890A MX 2012004890 A MX2012004890 A MX 2012004890A MX 2012004890 A MX2012004890 A MX 2012004890A MX 2012004890 A MX2012004890 A MX 2012004890A MX 2012004890 A MX2012004890 A MX 2012004890A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
adrenergic receptor
receptor agonist
alpha
acute erythema
Prior art date
Application number
MX2012004890A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Andres
Christian Loesche
Michael Graeber
Original Assignee
Galderma Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Pharma Sa filed Critical Galderma Pharma Sa
Publication of MX2012004890A publication Critical patent/MX2012004890A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012004890A 2009-10-26 2010-10-19 Metodos para tratar o prevenir eritema agudo. MX2012004890A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25480509P 2009-10-26 2009-10-26
PCT/US2010/053198 WO2011053487A1 (en) 2009-10-26 2010-10-19 Methods of treating or preventing acute erythema

Publications (1)

Publication Number Publication Date
MX2012004890A true MX2012004890A (es) 2012-09-28

Family

ID=43922456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004890A MX2012004890A (es) 2009-10-26 2010-10-19 Metodos para tratar o prevenir eritema agudo.

Country Status (12)

Country Link
US (1) US20110224216A1 (cg-RX-API-DMAC7.html)
EP (1) EP2493309A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013508454A (cg-RX-API-DMAC7.html)
KR (1) KR20120125230A (cg-RX-API-DMAC7.html)
CN (1) CN102711471A (cg-RX-API-DMAC7.html)
AU (1) AU2010313643B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012009891A2 (cg-RX-API-DMAC7.html)
CA (1) CA2779063A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012004890A (cg-RX-API-DMAC7.html)
NZ (1) NZ600125A (cg-RX-API-DMAC7.html)
RU (1) RU2012122983A (cg-RX-API-DMAC7.html)
WO (1) WO2011053487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
RU2587041C2 (ru) * 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
CA2827373C (en) 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EP2994120B1 (en) * 2013-05-06 2019-10-09 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
EP2962689B1 (en) * 2014-06-30 2018-04-11 Galderma S.A. Method of treating flushing associated with carcinoid tumors and carcinoid syndrome
CN106361733A (zh) * 2015-07-22 2017-02-01 刘里远 外用经穴激动剂
US10617688B2 (en) 2016-03-22 2020-04-14 Doris Maria HEXSEL Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas
FR3119986B1 (fr) * 2021-02-19 2024-02-16 Tarian Pharma Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911196B2 (en) * 2002-07-31 2005-06-28 Samir I. Hamtini Topical medicament for treating nappy rash
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050226899A1 (en) * 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US7709014B2 (en) * 2005-10-17 2010-05-04 Yu Ruey J Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
CN103298472A (zh) * 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
US20120101104A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel compositions and methods of use
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Also Published As

Publication number Publication date
BR112012009891A2 (pt) 2015-09-29
WO2011053487A1 (en) 2011-05-05
NZ600125A (en) 2014-05-30
CN102711471A (zh) 2012-10-03
AU2010313643B2 (en) 2015-11-12
EP2493309A1 (en) 2012-09-05
KR20120125230A (ko) 2012-11-14
AU2010313643A1 (en) 2012-06-07
JP2013508454A (ja) 2013-03-07
EP2493309A4 (en) 2013-05-01
RU2012122983A (ru) 2014-01-27
US20110224216A1 (en) 2011-09-15
CA2779063A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
AU2010313643B2 (en) Methods of treating or preventing acute erythema
EP2815748B1 (en) Compounds, formulations, and methods for treating or preventing rosacea
AU2005247467B2 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
JP2013538853A (ja) 酒瘡の併用による治療
CN105579042A (zh) 治疗皮肤增厚的方法
AU2012324544B2 (en) Method for treating capillary hemangiomas
MX2014004383A (es) Metodo para reducir el enrojecimiento facial asociado con el uso sistemico de inhibidores de fosfodiesterasa tipo 5.
HK1177102A (en) Methods of treating or preventing acute erythema
HK1164126B (en) Topical composition for use in the treatment of rosacea-induced redness
HK1204996B (en) Compounds, formulations, and methods for treating or preventing rosacea
HK1174537A (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
HK1084591B (en) Compounds, formulations, and methods for treating or preventing rosacea